The DOT1L inhibitor named Pinometostat (Epz-5676) was tested in Phase I/II clinical trials for treatment of MLLr leukaemia (clinical trial reference number NCT03701295 and NCT03724084 at https://clinicaltrials.gov), however withdrawn due to poor efficacy. This evidence concerns the gene DOT1L and leukemia.